Drug-coated Balloon Catheter Market Size, Share and Growth Outlook, 2026

Drug-coated Balloon Catheter Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Drug-coated Balloon Catheter Market size is forecast to increase from $1.73 Billion in 2026 to $3.23 Billion in 2034 at a CAGR of 8.1% between 2026 and 2034.

The Drug-coated Balloon Catheter market report provides detailed analysis and outlook of Drug-coated Balloon Catheter segments including By Product (Coronary Drug-coated Balloons, Peripheral Drug-coated Balloons, AV Access Drug-coated Balloons, Specialty and Lesion-Specific Balloons), By Drug Type (Paclitaxel-coated, Sirolimus-coated, Other Novel Agents), By Indication (In-Stent Restenosis, De-novo Lesions, Femoropopliteal Artery Disease, Below-the-Knee ), By End Use (Hospitals, Cardiac Catheterization Laboratories, Vascular Centers, Ambulatory Surgical Centers, Specialty Clinics) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Drug-Coated Balloon Catheter Industry Overview: Sirolimus Innovation and Regulatory Expansion in Endovascular Therapy

Sirolimus-Coated Balloon Catheters Demonstrating Clinical Safety and Efficacy

The drug-coated balloon catheter industry is witnessing a strong shift toward sirolimus-based technologies for cardiovascular interventions. Clinical trial results for the MagicTouch sirolimus-coated balloon (SCB) have demonstrated long-term safety and efficacy in treating coronary in-stent restenosis. These findings reinforce the clinical transition from paclitaxel-based coatings toward sirolimus as a preferred therapeutic agent due to its improved safety profile and sustained antiproliferative effects. The adoption of sirolimus-coated balloon platforms is strengthening interventional cardiology approaches by reducing restenosis rates and improving vessel patency outcomes in complex coronary procedures.

Regulatory Approvals Expanding Drug-Coated Balloon Use in Peripheral Artery Disease

Regulatory developments are accelerating the adoption of drug-coated balloon catheters for peripheral artery disease (PAD) treatment. The U.S. FDA has granted premarket approval for next-generation drug-coated balloon devices designed for use in the superficial femoral artery. This approval enables broader commercialization across hospital networks and supports expanded clinical utilization in endovascular interventions. The regulatory endorsement strengthens physician confidence in drug-coated balloon technologies and facilitates integration into standard treatment pathways for PAD management, particularly in patients with complex vascular lesions.

Clinical Guidelines Driving Adoption of Drug-Coated Balloon Technologies

Updated interventional guidelines from leading cardiovascular societies are significantly influencing the adoption of drug-coated balloon catheters in clinical practice. Recent European Society of Cardiology recommendations categorize drug-coated balloons as a preferred treatment modality for specific cases of coronary in-stent restenosis. This guideline update is reshaping hospital procurement strategies and accelerating clinical uptake across European healthcare systems. The formal inclusion of drug-coated balloons in treatment algorithms reflects growing clinical evidence supporting their efficacy and is driving standardization in interventional cardiology practice across global healthcare networks.

Drug-coated Balloon Catheter Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Drug-coated Balloon Catheter market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Medtronic, Boston Scientific Corporation, Abbott Laboratories, B. Braun Melsungen AG, Terumo Corporation, Cook Medical, Lepu Medical Technology, MicroPort Scientific Corporation, Biotronik, Acotec Scientific (Boston Scientific). The Drug-coated Balloon Catheter market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Drug-coated Balloon Catheter industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Drug-coated Balloon Catheter Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Drug-coated Balloon Catheter companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Drug-coated Balloon Catheter markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Drug-coated Balloon Catheter Market Competitive Benchmarking and Company Analysis

Leading companies in Drug-coated Balloon Catheter industry include- Medtronic, Boston Scientific Corporation, Abbott Laboratories, B. Braun Melsungen AG, Terumo Corporation, Cook Medical, Lepu Medical Technology, MicroPort Scientific Corporation, Biotronik, Acotec Scientific (Boston Scientific). The Drug-coated Balloon Catheter market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Drug-coated Balloon Catheter Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Drug-coated Balloon Catheter market remains one of the strongest-performing segments in the country.
The US Drug-coated Balloon Catheter Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Drug-coated Balloon Catheter market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Drug-coated Balloon Catheter industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Drug-coated Balloon Catheter markets

Canada's strong Drug-coated Balloon Catheter sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Drug-coated Balloon Catheter market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Drug-coated Balloon Catheter Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Drug-coated Balloon Catheter market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Drug-coated Balloon Catheter population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Drug-coated Balloon Catheter industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Drug-coated Balloon Catheter market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Drug-coated Balloon Catheter sales through 2034

France Drug-coated Balloon Catheter companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Drug-coated Balloon Catheter Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Drug-coated Balloon Catheter distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Drug-coated Balloon Catheter Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Drug-coated Balloon Catheter market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Drug-coated Balloon Catheter industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Drug-coated Balloon Catheter industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Drug-coated Balloon Catheter Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Drug-coated Balloon Catheter market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Drug-coated Balloon Catheter market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Drug-coated Balloon Catheter Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Drug-coated Balloon Catheter Market Segmentation

By Product
Coronary Drug-coated Balloons
Peripheral Drug-coated Balloons
AV Access Drug-coated Balloons
Specialty and Lesion-Specific Balloons
By Drug Type
Paclitaxel-coated
Sirolimus-coated
Other Novel Agents
By Indication
In-Stent Restenosis
De-novo Lesions
Femoropopliteal Artery Disease
Below-the-Knee
By End Use
Hospitals
Cardiac Catheterization Laboratories
Vascular Centers
Ambulatory Surgical Centers
Specialty Clinics

Top Companies in Drug-coated Balloon Catheter Industry

Medtronic
Boston Scientific Corporation
Abbott Laboratories
B. Braun Melsungen AG
Terumo Corporation
Cook Medical
Lepu Medical Technology
MicroPort Scientific Corporation
Biotronik
Acotec Scientific (Boston Scientific)

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025